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Sixteen laboratories carried out a collaborative study to validate 13/132 as a replacement International
Standard (IS) for TOXM (3rd IS for anti-Toxoplasma Serum, Human, 1000 IU). 13/132 is a freeze dried
preparation of pooled human plasma from six donors who experienced a recent Toxoplasma gondii
infection. The potency of 13/132 was compared to TOXM and 01/600 (1st IS for anti-Toxoplasma IgG,
Human, 20 IU). Samples were tested for IgA, IgG, IgG avidity and IgM in agglutination assays; enzyme
linked immunosorbent assays (ELISA), enzyme linked ﬂuorescent assays, immunoblots, immunoﬂuo-
rescence assays and the SabineFeldman dye test for Ig. 13/132 was strongly positive for Ig, IgA, IgG and
IgM and the reproducibility was very good. 13/132 contains high levels of anti-Toxoplasma Ig, IgG and
IgM and its potency falls between TOXM and 01/600. The avidity of IgG was found to be low, similar to
the avidity of IgG from TOXM. 13/132 was established by the Expert Committee on Biological Stan-
dardization as the 4th IS for Antibodies, Human, to T. gondii with an assigned unitage of 160 IU per
ampoule for Ig by dye test and 263 U per ampoule for IgG by ELISA.
© 2016 The Authors. Published by Elsevier Ltd on behalf of International Alliance for Biological
Standardization. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).1. Introduction
Toxoplasmosis is caused by the parasite Toxoplasma gondii.
Congenital transmission of T. gondii remains a considerable burden
on global health, with the highest incidence of 3.4/1000 births re-
ported for South America [1]. The main objective of screening pro-
grammes is to prevent infection of the foetus by the parasite during
pregnancy, and serology is widely used to diagnose Toxoplasmosis
during pregnancy [2]. In addition, toxoplasmosis is a major cause of
mortality among transplant patients [3]. The provision of appro-
priate antibody standards enables diagnostic laboratories andpert Committee on Biological
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c-nd/4.0/).manufacturers of diagnostic tests to validate serologic assays to di-
agnose this infection. In 1994, Hansen et al. carried out a collabo-
rative study to validate TOXM as a reference reagent for anti-
Toxoplasma Ig by SabineFeldman dye test. Each ampoule of TOXM
was assigned 1000 IU of anti-Toxoplasma Ig and subsequently
established as the 3rd International Standard (IS) by the Expert
Committee on Biological Standardization (ECBS) of theWorld Health
Organization [4]. The dye test is a complement-mediated cell killing
assay, utilising toxoplasma tachyzoites and does not distinguish
between immunoglobulin classes that bind complement [5].
Although the assay is now carried out by fewer laboratories, the dye
test is still considered a reference test and a conﬁrmatory assay to
validate commercial assays [6]. Therefore the dye test remains an
important assay for the standardisation of anti-toxoplasma Ig levels
in individuals suspected of toxoplasmosis. TOXM is used by manu-
facturers of in vitro diagnostic tests, national reference laboratories
and hospital laboratories. Since 2000, stocks of TOXMhave been low
and these are now nearly exhausted. In 2003, 01/600 was estab-
lished by ECBS as the 1st IS for anti-Toxoplasma IgGwith a unitage of
20 IU per ampoule relative to TOXM [7,8]. 01/600 has a low level of
IgG, which falls within the linear range of commercially availablece for Biological Standardization. This is an open access article under the CC BY-NC-
Table 1
Characterisation of samples used in this study.
Study
code
NIBSC code Description of source material Results of native material Results of freeze dried material
Dye testa (IU mL1) IgM ELISAb (EU mL1) Dye test (IU mL1) IgM ELISA (EU mL1)
TOXM TOXM 3rd IS for anti-Toxoplasma Ig Human e e 1000c e
A 01/600 1st IS for anti-Toxoplasma IgG Human e e 20c e
B 01/576 Pool of seven normal human sera e e <2c e
C and E 13/132 Candidate IS for antibodies, human, to T. gondii
from a pool of 6 plasma donationsd
794 (500e1000) 101 ± 12 561 (500e1000)ns 98 ± 7ns
D 174 Anti-Toxoplasma plasma from one donore 1000 105 ± 1 1000 125 ± 7
F 637 Anti-Toxoplasma plasma from one donore 250 94 ± 6 500 101 ± 7
ns: Differences between native and freeze dried samples are not signiﬁcant.
e: Not done.
a Lab code 6.1. Results given as geometric mean titre (range).
b Lab code 6.2. Results given as geometric mean ELISA Unit (EU) ± standard deviation: > 40: positive; >100: strongly positive (12).
c Taken from Rigsby et al., 2004 [8].
d Taken from 6 measurements over three days.
e Taken from 2 measurements over two days.
S. Rijpkema et al. / Biologicals 44 (2016) 448e455 449immunoassays used by diagnostic laboratories to distinguish be-
tween historic, background and diagnostic levels of IgG. Although,
the unitage of 01/600 can be traced back to the 2nd IS TOXS, ECBS
did not consider IS 01/600 a suitable replacement for TOXM because
of the low levels of speciﬁc IgG and absence of speciﬁc IgM. The
committee decided that a replacement for TOXM should contain
high levels of IgM and IgG [4,7,8].
Recently, plasma samples from acute cases of Toxoplasmosis
were acquired and a preliminary analysis showed that individual
samples and the pooled sample 13/132, contained high levels of
speciﬁc IgM and IgG, the latter with low to borderline avidity (see
Table 1 and results not shown). Speciﬁc IgG of high avidity is seen as
a marker of latent toxoplasmosis, whereas IgG of low avidity can be
indicative of a recent infection [9,10]. A collaborative study was
designed to validate 13/132 as an IS to replace TOXM. Participants
were asked to test 13/132 in the dye test, and in addition were
encouraged to use assays that are part of their diagnostic routine.
The primary aims of the study were to:
1) assess the suitability of 13/132 as an IS for human anti-
Toxoplasma Ig.
2) compare the reactivity of 13/132 relative to TOXM and 01/600 in
the dye test.
3) compare the reactivity of 13/132 relative to TOXM and 01/600 in
immunoassays for IgM and IgG, including avidity assays.
4) assess the reactivity of 13/132 in agglutination assays, immu-
noassays and in other titration assays currently in use.2. Materials and methods
2.1. Participating laboratories and assay codiﬁcation
Sixteen laboratories from 12 countries, including national refer-
ence laboratories, took part in the collaborative study. Details are
given in the acknowledgement section. Throughout the study,
participating laboratories were identiﬁed by a randomly assigned
code number to maintain conﬁdentiality. Data were collected and
analysed at the National Institute for Biological Standards and Con-
trol (NIBSC). Each participant received two sets of seven samples
comprising coded ampoules A to F including 01/600 (A) and dupli-
cates of 13/132 (C and E), and one ampoule of TOXM (see Table 1).
2.2. Samples used in the study
Samples labelled A to F and TOXM were distributed as lyophi-
lised preparations in duplicate sample packs by courier at roomtemperature. The samples were reconstituted following ‘in-
structions for use’ issued by NIBSC. Samples of 13/132 that were
exposed to an elevated temperature range (20 C to þ45 C) to
ascertain stability of the active component were distributed on dry
ice. A brief characterisation of the samples, study codes,
NIBSC codes and their reactivity in the dye test and the IgM capture
enzyme linked immunosorbent assay (ELISA) are given in Table 1.2.3. Characterisation of the proposed International Standard 13/132
Plasma samples were donated with informed consent by 6 fe-
male individuals of 21e33 years of age and obtained from Cerba
Specimen Services (Saint-Ouen l'Aumo^ne, France). At NIBSC, all
samples tested negative for antibodies to Human Immunodeﬁ-
ciency Virus 1 and 2, Hepatitis C RNA and Hepatitis B surface an-
tigen. Samples were stored at 80 C until further use. Prior to
pooling, samples were defrosted and stored at 2e8 C overnight.
The next day, samples were pooled (volume appr. 3 L) during which
clotting occurred. Clots were removed by a ﬁltration step using
Whatman ﬁlter paper (1001-150). The ﬁltrate of the pool was
stored at 2e8 C overnight and dispensed in 0.5 mL aliquots into
glass ampoules coded 13/132 on the following day. The mean ﬁll
weight for 123 ampoules was 0.5156 g (CV of 0.16%). On the same
day, freeze-drying under vacuum was started and completed after
four days. Ampoules were back ﬁlled with pure N2 and themean O2
content of 12 ampoules was 0.17% (CV of 53.71%). This implies
ampoules passed the test for integrity, because the presence of
cracks would be associated with an O2 level of 21% similar to that
found in the atmosphere. The mean residual moisture level in 12
ampoules was 0.6608% (CV of 18.89%). One hundred and sixty
ampoules were rejected during the production process, 50 am-
poules were held for accelerated degradation studies and 3695
ampoules were stored at 20 C. These are available for distribu-
tion by NIBSC.
Native and freeze-dried samples of 13/132 and individual
samples 174 (D) and 637 (F), which are part of the serum pool,
were tested by dye test and IgM capture ELISA to determine the
effect of freeze drying on speciﬁc Ig and IgM respectively (see
Table 1). No signiﬁcant differences in the mean values for levels of
speciﬁc IgM and Ig were found before and after freeze-drying.
Differences in unitage determined by dye test were found
following freeze drying for samples C and E (13/132) and samples
D and F. These fall within the four fold range and are therefore not
considered signiﬁcant.
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An overview of the 24 assay formats used for the detection of
anti-T. gondii antibodies and their laboratory code is given in
Table 2. Titration methods were represented by seven assay for-
mats. Five assays were developed in-house: the dye test for Ig, the
high sensitivity direct agglutination assay (HSDA) for IgG [11],
immunoﬂuorescence assays (IFA) for IgG and IgM, and the imu-
nosorbent agglutination assay (ISAGA) for IgA and IgM [12]; the
Toxoreagent kit for IgG/IgM (Mast) and the ISAGA for IgM (bio-
Merieux) are commercially available.
Six ELISA and enzyme linked ﬂuorescent assay (ELFA) formats
were used to detect IgM; four assays are commercially available
(Abbot, bioMerieux, Biorad and Diasorin) and two capture ELISAs
were developed in-house [13,14]. Eight ELISAs and ELFAs, including
avidity assays, were used to detect speciﬁc IgG: ﬁve of these are
commercially available (Abbot, bioMerieux, Diasorin) and three
ELISAs were developed in-house. Immunoblots were used for the
detection of IgG (LDBio Diagnostics) and IgM [15]. One competition
ELFA (bioMerieux) was used to detect Ig.
2.5. Data analysis
Samples were tested in duplicate on two different days. Data
sets containing raw data, transformed data and operating pro-
cedures were submitted to NIBSC for analysis. For the majority of
methods, reported results (endpoint titres, potencies in IU or ELISA
Units [EU] etc.) were converted directly into relative potencies by
dividing by the result obtained for the appropriate standard. For
IgM data, relative results (given as index, signal/cut off ratio etc)
are shown for ELFAs and ELISAs and these cannot be directly
interpreted as relative potency. ELISA data from lab 3 were ana-
lysed by parallel line bioassay comparing assay response to log
concentration in a four-parameter logistic model using version 5.0Table 2
Assays used in this study.
Type of test Manufacturer and name of the test, antibody speciﬁcity (n)
Titration assays (8)
Agglutination assay In-house, HSDA,a IgG (2)
bioMerieux ISAGA,b IgM (4)
In-house, ISAGA, IgA (1)
In-house, ISAGA, IgM (2)
MAST Latex toxoreagent, IgG/IgM (1)
Dye test
IFAc
In-house, Ig (6)
In-house, IgG (1)
In-house, IgM (1)
Enzyme immunoassays and enzyme linked ﬂuorescent assays (15)
ELFAd bioMerieux VIDAS Toxo Competition (1)
bioMerieux VIDAS Toxo IgG II (9)
bioMerieux VIDAS Toxo IgG Avidity (1)
bioMerieux VIDAS Toxo IgM (10)
ELISAe Abbott ARC Toxo IgG (2)
Abbott ARC Toxo IgG Avidity (1)
Abbott ARC Toxo IgM (2)
Bio Rad Platelia Toxo IgM (1)
Diasorin Liaison Toxo IgG (1)
Diasorin Liaison Toxo IgM II (1)
In-house, IgG (2)
In-house, IgG avidity (1)
In-house, IgM capture (2)
Immunoblot In-house, IgM (1)
LDBio Diagnostics IgG (1)
a High sensitivity direct agglutination assay [11].
b Imunosorbent agglutination assay [12].
c Immunoﬂuorescence assay.
d Enzyme linked ﬂuorescent assay.
e Enzyme linked immunosorbent assay.of EDQM's CombiStats software [16]. The ﬁnal estimate in each
assay for 13/132 was taken as the geometric mean (GM) of the two
coded duplicates (C and E). All mean estimates shown in
this report are unweighted GM estimates. Variability between
laboratories has been expressed using geometric coefﬁcients of
variation (GCV) ¼ {10s  1}  100% where s is the standard devi-
ation of the log10-transformed estimates.
3. Results and discussion
3.1. Titration assays
Titration assays were carried out by 11 laboratories and all re-
ported results for TOXM and samples A to F. All participants
correctly identiﬁed sample B as negative. The potencies of the
coded positive samples relative to TOXM, 01/600 and 13/132 are
summarised in Table 3. Participant 14 did not identify TOXM and
01/600 as positive by dye test and the data of lab code 14.1 were
therefore not included in the calculation of the relative potency of
13/132. In addition, data sets which did not contain numerical
values for TOXM or 01/600, or which qualiﬁed samples A to F as
positive or negative were not included in the calculation of the
relative potency of 13/132.
Analysis of the dye test and the IFA results for duplicates C and E
(13/132) showed that the potency of C relative to E fell within a
two-fold difference relative to 1 (range 0.5e2.0) in all laboratories
but one, which indicates adequate diagnostic precision among
participating laboratories. Commercial and in-house agglutination
assays performed better than the dye test in this respect (see Fig. 1).
Hansen et al. assigned a unitage of 1000 IU per ampoule TOXM
for Ig [4]. The potency of anti-Toxoplasma Ig in sample A (01/600)
relative to TOXM is reported as 0.02, which is equal to a unitage of
20 IU per ampoule and identical to the unitage assigned to 01/600
in a previous collaborative study [7,8,17]. 13/132 (C and E) had a GMParticipant code Lab code
5, 9 5.1, 9.1
4, 5, 7, 11 4.1, 5.2, 7.1, 11.1
9 9.2
2, 9 2.1, 9.3
4 4.2
1, 2, 3, 6, 10, 14 1.1, 2.2, 3.1, 6.1, 10.1, 14.1
7 7.2
7 7.3
13 13.1
1, 2, 5, 7, 8, 10, 12, 13, 16 1.1, 2.2, 5.3, 7.4, 8.1, 10.2, 12.3, 13.2, 16.1
16 16.2
1, 2, 5, 7, 8, 10, 12, 13, 15, 16 1.2, 2.3, 5.4, 7.5, 8.2, 10.3, 12.4, 13.3, 15.3, 16.3
11, 12 11.2, 12.1
11 11.3
11, 12 11.4, 12.2
4 4.3
11 11.5
11 11.6
4, 15 4.4, 15.1
15 15.2
3, 6 3.2, 6.2
4 4.5
11 11.7
Table 3
Summary of results from titration assays for samples A to F relative to TOXM, 01/600 and 13/132.
Assay (antibody) Test sample A (01/600) C/E (13/132) D F
Reference TOXM TOXM 01/600 (A) TOXM 01/600 (A) 13/132 (C/E) TOXM 01/600 (A) 13/132 (C/E)
Dye test (Ig) Lab code 1.1 0.02 0.54 28.8 0.77 40.7 1.41 0.24 12.8 0.45
Lab code 2.2 0.03 0.28 8.8 0.50 15.6 1.78 0.25 7.8 0.89
Lab code 3.1 0.02 0.33 21.1 0.23 14.9 0.71 0.20 12.5 0.59
Lab code 6.1 0.02 0.32 19.7 0.63 39.4 2.00 0.25 15.6 0.79
Lab code 10.1 0.03 0.21 6.7 0.35 11.3 1.68 0.31 9.8 1.46
GMa 0.02 0.32 14.78 0.46 21.15 1.43 0.25 11.40 0.77
GCVb 42.7% 41.0% 85.9% 60.7% 81.4% 51.2% 17.3% 30.7% 56.1%
Latex MAST (IgM, IgG) Lab code 4.2 0.55 0.42 15.4 0.50 18.3 1.19 0.35 13.0 0.84
IFA (IgM) Lab code 7.3 Not done 0.50 Not done 0.42 Not done 0.84 0.42 Not done 0.84
ISAGA (IgM) Lab code 2.1 Not done 0.26 Not done 0.26 Not done 1.00 0.26 Not done 1.00
IFA (IgG) Lab code 7.2 0.01 0.42 67.3 0.50 80.0 1.19 0.25 40.0 0.59
HSDA (IgG) Lab code 5.1 0.06 0.50 8.0 0.50 8.0 1.00 0.50 8.0 1.00
Lab code 9.1 0.02 0.13 6.7 0.36 19.0 2.83 0.25 13.5 2.00
GMa 0.03 0.25 7.3 0.42 12.3 1.68 0.35 10.4 1.41
a GM: geometric mean.
b GCV: geometric coefﬁcients of variation.
Fig. 1. Relative results of coded duplicate samples C and E (representing 13/132) are presented for various assays. Most ratios fall within the twofold range (50e200%) relative to a C/
E ratio of 1. Only participant 10 reported results for the dye test that exceeded this range. In general, the highest precisions were achieved by commercial ELISAs and ELFAs.
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and a potency of 14.78 with a GCV of 85.9% relative to 01/600
(Table 3). The calculated unitage of 13/132 for Ig is therefore
320 IU mL1 or 160 IU per ampoule relative to TOXM and
296 IU mL1 or 148 IU per ampoule relative to 01/600.
The relative potency of 13/132 compared to TOXM varied in
other agglutination assays. Compared to the dye test, the Tox-
oreagent kit (Mast) gave the closest results for samples C and E
(13/132), D and F. This assay does not distinguish between IgG and
IgM, whereas IFA and ISAGA speciﬁcally detect either IgG or IgM.
Thus the differences in unitage for the latter two assays may
reﬂect differences in assay procedures and in antibody classes
detected.3.2. Enzyme immunoassays and enzyme linked ﬂuorescent assays
All participants who carried out ELISAs and ELFAs to detect IgM
or IgG reported results for TOXM and samples A to F. Sample B was
reported as negative for IgM and IgG. The results of quantitative
assays, which failed to assign a numerical value to TOXM, were not
used to assign a unitage and are excluded from Tables 4 and 5. The
results of qualitative assays for IgG and IgM are presented in
Table 6.
Sample A (01/600) was reported as negative for IgM by in-house
ELISAs but in commercial assays a very low value for IgM relative to
TOXMwas reported (see Table 4). The results of 13/132 and samples
D and F for IgM relative to TOXM, 01/600 and 13/132 are sum-
marised in Table 4. As mentioned above, the low IgM values of 01/
600 resulted in artiﬁcially high IgM values for 13/132 and samples D
and F. These ﬁgures should thus be considered for information only.
Table 4
Summary of IgM results in ELISA and ELFA for samples A to F relative to TOXM, 01/600 and 13/132.
Assay Test sample A (01/600) C/E (13/132) D F
Reference TOXM TOXM 01/600 (A) TOXM 01/600 (A) 13/132 (C/E) TOXM 01/600 (A) 13/132 (C/E)
bioMerieux VIDAS Toxo IgM Lab code 1.2 0.01 0.76 53.0 0.72 50.0 0.94 0.85 59.3 1.12
Lab code 2.3 0.02 0.79 48.7 0.76 46.3 0.95 0.87 53.1 1.09
Lab code 5.4 0.02 0.77 45.0 0.75 43.6 0.97 0.99 21.5 1.01
Lab code 7.5 0.02 0.76 49.6 0.73 47.7 0.96 0.87 50.8 1.13
Lab code 8.2 0.02 0.80 53.9 0.81 52.9 0.98 0.95 63.0 1.17
Lab code 10.3 0.01 0.69 61.4 0.66 59.8 0.97 0.79 69.3 1.13
Lab code 12.4 0.01 0.76 51.7 0.75 51.0 0.99 0.84 57.4 1.11
Lab code 13.3 0.01 0.74 50.8 0.72 49.2 0.97 0.85 58.2 1.15
Lab code 15.3 0.01 0.74 57.1 0.73 55.1 0.97 0.85 64.6 1.13
Lab code 16.3 0.01 0.72 49.5 0.72 50.2 1.01 0.80 55.2 1.11
GMa 0.01 0.75 51.9 0.73 50.4 0.97 0.85 58.6 1.13
GCVb 12.3% 4.5% 9.1% 5.0% 9.3% 2.0% 5.1% 9.8% 2.0%
Abbott ARC Toxo IgM Lab code 11.4 0.01 0.53 79.2 0.45 68.0 0.86 0.67 100.3 1.27
Lab code 12.2 0.01 0.45 65.6 0.36 52.7 0.80 0.57 82.7 1.26
GMa 0.01 0.49 72.1 0.41 59.9 0.83 0.62 91.1 1.26
Biorad Platelia Lab code 4.3 0.05 0.98 21.3 0.97 21.0 0.99 0.99 21.5 1.01
IgM capture ELISA Lab code 3.2 Negative 0.25 Negative 0.20 Negative 1.02 0.25 Negative 0.93
Lab code 6.2 Negative 0.67 Negative 0.70 Negative 1.04 0.64 Negative 0.95
GMa e 0.41 e 0.37 e 1.03 0.40 e 0.94
a GM: geometric mean.
b GCV: geometric coefﬁcients of variation.
Table 5
Summary of IgG results in ELISA and ELFA for samples A to F relative to TOXM, 01/600 and 13/132.
Assay Test sample A (01/600) C/E (13/132) D F
Reference TOXM TOXM 01/600 (A) TOXM 01/600 (A) 13/132 (C/E) TOXM 01/600 (A) 13/132 (C/E)
bioMerieux VIDAS Toxo IgG II Lab code 1.1 0.20 0.36 1.82 0.39 1.98 1.09 0.46 2.37 1.30
Lab code 2.2 0.36 0.58 1.64 0.63 1.77 1.08 0.98 2.75 1.67
Lab code 5.3 0.20 0.41 2.01 0.49 2.38 1.18 0.77 3.77 1.87
Lab code 7.4 0.46 0.67 1.46 0.72 1.57 1.08 0.91 1.98 1.36
Lab code 8.1 NNVa NNVa 1.74 NNVa 2.29 1.32 NNVa 3.29 1.36
Lab code 10.2 0.34 0.69 1.83 0.72 1.95 1.06 0.88 2.59 1.41
Lab code 12.3 0.40 0.67 1.68 0.68 1.70 1.01 0.94 2.34 1.40
Lab code 13.2 0.10 0.49 5.05 0.57 5.94 1.18 0.73 7.60 1.50
Lab code 16.1 0.36 0.61 1.72 0.58 1.61 0.94 0.97 2.72 1.58
GMb 0.27 0.55 1.95 0.59 2.14 1.10 0.81 3.01 1.49
GCVc 68.2% 28.5% 44.4% 24.1% 50.5% 10.3% 28.4% 48.5% 12.5%
Abbott ARC Toxo IgG Lab code 11.2 0.04 0.23 5.84 0.28 7.35 1.26 0.26 6.85 1.17
Lab code 12.1 NNVa NNVa 5.75 NNVa 7.14 1.24 NNVa 6.68 1.16
GMb 5.80 7.24 1.25 6.77 1.17
Diasorin Liaison Toxo IgG Lab code 11.5 0.29 0.53 1.83 0.53 1.83 1.00 0.66 2.28 1.25
IgG ELISA Lab code 4.4 0.84 0.62 0.74 0.55 0.65 0.88 1.54 1.83 2.48
Lab code 15.1 0.42 0.75 1.79 0.73 1.74 0.97 0.88 2.10 1.18
a NNV: TOXM result fell outside assay range and no numerical value was given.
b GM: geometric mean.
c GCV: geometric coefﬁcients of variation.
Table 6
Results of qualitative assays for TOXM and samples A to F.
Lab code and assay Antibody detected Test sample
A B C D E F TOXM
4.1 bioMerieux ISAGA IgM   þ þ þ þ þ
4.5 Immunoblot IgM   þ þ þ þ þ
5.2 bioMerieux ISAGA IgM   þ þ þ þ þ
7.1 bioMerieux ISAGA IgM   þ þ þ þ þ
9.2 ISAGA IgA   þ þ þ þ þ
9.3 ISAGA IgM   þ þ þ þ þ
11.1 bioMerieux ISAGA IgM   þ þ þ þ þ
11.7 LDBio Diagnostics Immunoblot IgG þ  þ þ þ þ þ
13.1 bioMerieux VIDAS Toxo Competition Ig þ  þ þ þ þ þ
S. Rijpkema et al. / Biologicals 44 (2016) 448e455452The ratio of the results of coded duplicate samples of 13/132 (C
and E) in ELFAs, ELISAs and agglutination assays are shown in Fig. 1.
These show that commercial ELFAs and ELISAs have a high level ofprecision and reproducibility compared to in-house ELISAs. All
assay results fell within a two-fold difference relative to 1 (range
S. Rijpkema et al. / Biologicals 44 (2016) 448e455 4530.5e2.0), an indication of good diagnostic precision among
participating laboratories.
Based on 10 data sets generated by the bioMerieux VIDAS Toxo
IgM ELFA, 13/132 had a GM relative result of 0.75 with a GCV of
4.5% relative to TOXM (Table 4). The relative results for samples D
and F for IgM were close to that of 13/132. Two data sets from the
Abbott ARC Toxo IgM ELISA and in-house IgM capture ELISAs gave
a lower GM values for 13/132 of 0.49 and 0.41 respectively. The
relative results for samples D and F for IgM were also close to 13/
132 in this assay. The GCVs of the results of samples D and F in
the bioMerieux VIDAS Toxo IgM ELFA were lower when 13/132
was used as reference compared to TOXM.
Hansen et al. estimated the unitage of TOXM for IgM to be 3000
units mL1 [4]. In this study, results for IgM assays were reported as
indices of signal to noise ratios, with the exception of one IgM
capture ELISA by lab 3.2, which reported results in ODs. Based on
this data set the potency of IgM for 13/132 relative toTOXM is 0.250,
equal to 750 units mL1 or 375 units per ampoule (see Table 4). Due
to the limited amount of data and the fact that a unitage for IgM had
not been assigned toTOXM,we conclude that 13/132 has a high IgM
content and can be considered as a reference reagent but not as an
IS for IgM.
The potencies of 13/132 and samples D and F for IgG relative to
TOXM, 01/600 and 13/132 are summarised in Table 5. Based on 9
data sets from the bioMerieux VIDAS Toxo IgG II ELFA, 13/132 had a
GM potency value of 0.55 with a GCV of 28.5% relative to TOXM
and a GM potency value of 1.95 with a GCV of 44.4% relative to 01/
600 (Table 5). The relative potency of sample D for IgG was close to
13/132. The relative potencies of sample F for IgG were consider-
ably higher then those for 13/132 in this assay (Table 5). The GCVs
of the results of samples D and F in the bioMerieux VIDAS Toxo IgG
II ELFA were lower when 13/132 was used as reference compared
to TOXM.
Hansen et al. estimated a possible unitage of TOXM for IgG to be
1000 IU mL1 [4]. Based on 12 data sets, we calculated the relative
potency of 13/132 for IgG as 0.525 (range 0.23e0.75) this corre-
sponds to 525 units mL1 or 263 units per ampoule (see Table 5).
However if the potency of 13/132 for IgG is estimated relative to 01/
600 then the GM unitage is considerably lower at 15e116 units
mL1 (Table 5). This difference is likely to be caused by the presence
of IgM and IgA in TOXM and in 13/132. Both Ig classes will compete
with IgG for binding to exposed epitopes in ELISA but not in the dye
test, whereas in 01/600 these Ig classes are absent thus allowing a
relative high proportion of speciﬁc IgG to bind in ELISAs [8]. Due to
the fact that a unitage for IgG had not been assigned to TOXM, we
conclude that 13/132 can be considered as a reference reagent but
not as an IS for IgG.
The avidity of IgG in 13/132 was assessed by ELISA and ELFA
and the results of three assays are presented in Table 7. The
avidity of IgG in samples C to F was found to be low in 2 out of 3Table 7
Results of avidity IgG ELISAs for samples A to F and TOXM.
Lab code and assay 11.3 Abbott ARC Toxo IgG avidity (%)a 16.1
Sample tested
TOXM 22.7 (Low) 0.07
A (01/600) 82.4 (High) 0.49
C/E (13/132) 34e38.4 (Low) 0.13
D 30.1 (Low) 0.11
F 51.9 (Grey zone) 0.21
a Avidity index: Low <50.0%; Grey zone 50.0e59.9%; High 60.0%.
b Avidity index: Low <0.200; Intermediate 0.200 & <0.300; High 0.300.
c Avidity index: Low <30; Borderline 30e40; High >40.assays and similar to the avidity of IgG from TOXM. Indeed,
Hansen et al. postulated that IgG from TOXM was of low avidity.
By contrast the avidity of IgG from 01/600 (A) is considerably
higher, pointing to a historic infection. It was noted that low
avidity of IgG in combination with a high IgG content contributes
to the inter-laboratory variability for 13/132 in diagnostic assays
for IgG (see Table 5).3.3. Qualitative immunoassays
The presence of Ig, IgA, IgG or IgM was also detected by quali-
tative assays, including capture ELISAs, a competition ELFA,
immunoblot assays and ISAGAs. The results are presented in Table 7
and Fig. 2. Results of qualitative assays indicated the presence of
anti-Toxoplasma antibodies in TOXM and samples A and C to F and
are in agreement with the outcome of quantitative ELISAs and
agglutination assays. For example, the immunoblot for IgG (lab
code 11.7) conﬁrmed the presence of IgG in TOXM, samples A and C
to F by ELISA, HDSA and IFA. The immunoblot for IgM (lab code 4.5)
conﬁrmed the presence of IgM in TOXM and samples C to F. Speciﬁc
IgM bound to a 6 kilo Dalton (kD) antigen of T. gondii (see Fig 2).
Previous work by Sharma et al. demonstrated that IgM but not IgG
from patients with toxoplasmosis reacts with the 6 kD antigen.
Hence this reactivity is deemed a diagnostic marker of acute
infection [18]. Herbrink et al. showed that the IgM immunoblot can
be used to conﬁrm results of IgM capture ELISAs [15]. Data pre-
sented here, extend this to IgM detected by IFA and ISAGA.3.4. Stability studies
Samples of 13/132 were stored for 481 days (~15.3 months)
at 20 C and at elevated temperatures þ4 C, þ20 C, þ37 C
andþ45 C. Two samples exposed to each temperature were tested
in duplicate in the dye test (lab code 6.1) and in-house IgM ELISA
(lab code 6.2 [14]). The potency of the samples, subjected to
accelerated thermal degradation, was calculated relative to the
samples stored at 20 C and is given in Table 8.
These results were used to ﬁt Arrhenius equations relating the
degradation rate to absolute temperature assuming ﬁrst-order
decay and hence predict the degradation rates when stored
at 20 C [19]. Data from the dye test showed predicted losses of
potency of <0.01%, 0.10%, 0.65% and 3.77% per month and 0.05%,
1.16%, 7.27% and 36.0% per year at storage temperatures
of 20 C, þ4 C, þ20 C and þ37 C respectively. Data from the in-
house IgM ELISA cannot be directly interpreted as relative potency
and are presented for information only.bioMerieux VIDAS Toxo IgG avidity (OD)b 15.2 IgG avidity ELISA (%)c
9 (Low) 27 (Low)
6 (High) 59 (High)
9e0.149 (Low) 42 (Borderline)
9 (Low) 35 (Borderline)
8 (Intermediate) 47 (High)
Fig. 2. IgM immunoblot (lab code 4.5) of duplicates of TOXM (Tx) and coded samples A to F, with T. gondii strain RH as antigen. The presence of the 6 kD band denotes an IgM
positive sample (8). The numbers in subscript indicate the duplicates per sample pack.
Table 8
Test results for samples of candidate IS 13/132 stored at elevated temperatures for approximately 15.3 months.
Lab code and test Storage temperature Resulta Range Geometric mean titre Geometric mean titre relative to 20 C
Day 1 Day 2 Day 3
6.1
Dye test (IU mL1)
20 C 500 500 500 500 500 e
þ4 C 500 500 500 500 500 1.00
þ20 C 500 375 500 250e500 445 0.89
þ37 C 375 250 250 250e500 281 0.56
þ45 C 125 125 188 125e250 140 0.28
6.2
IgM capture
ELISA (EU mL1)
20 C 91 98 94 91e101 94 e
þ4 C 96 94 96 92e101 95 1.01
þ20 C 85 85 88 81e90 86 0.92
þ37 C 51 52 60 50e62 55 0.58
þ45 C 5b 18 22 4e23 12 0.13
a Average result of two vials is given.
b Reconstituted material stored at þ45 C was highly viscous on day 1 prohibiting accurate pipetting of volumes. The viscosity decreased after a 24 h incubation at þ4 C,
allowing accurate pipetting of the sample on day 2 and 3.
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Standardization
Relative toTOXM, a unitage for Ig by dye test was assigned to 13/
132 of 160 IU per ampoule or 320 IU mL1 (GCV of 41.0%). The
avidity of IgG is low and comparable to the avidity of IgG from
TOXM. 13/132 contains high levels of anti-Toxoplasma IgG and IgM
thus allowing calibration in terms of IgG and IgM and its potency
falls between TOXM and 01/600. Therefore, 13/132 meets the re-
quirements for a replacement of TOXM as set out by ECBS in 2003
[7]. 13/132 will be a useful addition for the standardisation of
Toxoplasma serology and support appropriate clinical management
of this disease and 13/132 was proposed as the 4th IS for Anti-
bodies, Human, to T. gondii to replace TOXM. A collaborative study
report with these ﬁndings was submitted to ECBS [20].
ECBS discussed the long term stability of IgM, the current
limited use of the dye test compared to former times, and the
problems a high IgG titre might cause for current assays. ECBS
concluded that the stability issue of IgM is only apparent ataccelerated conditions at late time points. Since 13/132 is a
replacement standard, comparison by the dye method is justiﬁed.
ECBS suggested that the unitage proposed for IgG and IgMmight be
used for information only. However, IgM assays are known to be
more challenging to harmonise than IgG assays and a unitage for
IgM may be misleading. Thus, for IgM only a high titre should be
indicated.
In October 2015, ECBS endorsed the establishment of 13/132 as
the 4th IS for Antibodies, Human, to T. gondii to replace TOXM, with
an assigned unitage of 160 IU per ampoule and an IgG content of
263 U per ampoule relative to TOXM. A high content of IgM was
noted. The committee recommended that a potential replacement
standard be developedwith unitage for IgG and IgM suitable for use
with current analytical methods.
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